Literature DB >> 25209159

A novel splice mutation in PLS3 causes X-linked early onset low-turnover osteoporosis.

Christine M Laine1, Maija Wessman, Sanna Toiviainen-Salo, Mari A Kaunisto, Mervi K Mäyränpää, Tero Laine, Minna Pekkinen, Heikki Kröger, Ville-Valtteri Välimäki, Matti J Välimäki, Anna-Elina Lehesjoki, Outi Mäkitie.   

Abstract

Genetic factors play an important role in the development of osteoporosis. Several monogenic forms of osteoporosis have been recognized, most recently an X-chromosomal form resulting from mutations in the gene encoding plastin 3 (PLS3). PLS3 is a protein involved in actin bundle formation in the cytoskeleton. We present a large family with early onset osteoporosis and X-linked inheritance. Phenotyping was performed on 19 family members and whole-exome sequencing on 7 family members (5 with a diagnosis of early onset osteoporosis and 2 with normal bone parameters). Osteoporosis had its onset in childhood and was characterized by recurrent peripheral fractures, low bone mineral density (BMD), vertebral compression fractures, and significant height loss in adulthood. Males were in general more severely affected than females. Bone histomorphometry findings in 4 males and 1 female showed severe trabecular osteoporosis, low amount of osteoid, and decreased mineral apposition rate, indicating impaired bone formation; resorption parameters were increased in some. All affected subjects shared a single base substitution (c.73-24T > A) in intron 2 of PLS3 on Xq23. The mutation, confirmed by Sanger sequencing, segregated according to the skeletal phenotype. The mutation introduces a new acceptor splice site with a predicted splice score of 0.99 and, thereby, as confirmed by cDNA sequencing, induces the insertion of 22 bases between exons 2 and 3, causing a frameshift and premature termination of mRNA translation (p.Asp25Alafs*17). The mutation affects the first N-terminal calcium-binding EF-hand domain and abolishes all calcium- and actin-binding domains of the protein. Our results confirm the role of PLS3 mutations in early onset osteoporosis. The mechanism whereby PLS3 affects bone health is unclear, but it may be linked to osteocyte dendrite function and skeletal mechanosensing. Future studies are needed to elucidate the role of PLS3 in osteoporosis and to define optimal treatment.
© 2014 American Society for Bone and Mineral Research.

Entities:  

Keywords:  BIOCHEMICAL MARKERS OF BONE TURNOVER; BONE HISTOMORPHOMETRY; CELLS OF BONE; GENETIC RESEARCH; OSTEOPOROSIS

Mesh:

Substances:

Year:  2015        PMID: 25209159     DOI: 10.1002/jbmr.2355

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  29 in total

Review 1.  Bone biology: insights from osteogenesis imperfecta and related rare fragility syndromes.

Authors:  Roberta Besio; Chi-Wing Chow; Francesca Tonelli; Joan C Marini; Antonella Forlino
Journal:  FEBS J       Date:  2019-07-05       Impact factor: 5.542

2.  Two novel mutations in TMEM38B result in rare autosomal recessive osteogenesis imperfecta.

Authors:  Fang Lv; Xiao-Jie Xu; Jian-Yi Wang; Yi Liu; Jia-Wei Wang; Li-Jie Song; Yu-Wen Song; Yan Jiang; Ou Wang; Wei-Bo Xia; Xiao-Ping Xing; Mei Li
Journal:  J Hum Genet       Date:  2016-02-25       Impact factor: 3.172

3.  A novel frameshift deletion in PLS3 causing severe primary osteoporosis.

Authors:  Alice Costantini; Panagiotis Ν Krallis; Anders Kämpe; Emmanouil M Karavitakis; Fulya Taylan; Outi Mäkitie; Artemis Doulgeraki
Journal:  J Hum Genet       Date:  2018-06-08       Impact factor: 3.172

Review 4.  The genetics of bone mass and susceptibility to bone diseases.

Authors:  David Karasik; Fernando Rivadeneira; Mark L Johnson
Journal:  Nat Rev Rheumatol       Date:  2016-04-07       Impact factor: 20.543

Review 5.  Insights from exome sequencing for endocrine disorders.

Authors:  Christiaan de Bruin; Andrew Dauber
Journal:  Nat Rev Endocrinol       Date:  2015-05-12       Impact factor: 43.330

6.  A novel large fragment deletion in PLS3 causes rare X-linked early-onset osteoporosis and response to zoledronic acid.

Authors:  F Lv; M Ma; W Liu; X Xu; Y Song; L Li; Y Jiang; O Wang; W Xia; X Xing; Z Qiu; M Li
Journal:  Osteoporos Int       Date:  2017-06-16       Impact factor: 4.507

7.  Osteocyte Protein Expression Is Altered in Low-Turnover Osteoporosis Caused by Mutations in WNT1 and PLS3.

Authors:  Katherine Wesseling-Perry; Riikka E Mäkitie; Ville-Valtteri Välimäki; Tero Laine; Christine M Laine; Matti J Välimäki; Renata C Pereira; Outi Mäkitie
Journal:  J Clin Endocrinol Metab       Date:  2017-07-01       Impact factor: 5.958

Review 8.  Recent Discoveries in Monogenic Disorders of Childhood Bone Fragility.

Authors:  Riikka E Mäkitie; Anders J Kämpe; Fulya Taylan; Outi Mäkitie
Journal:  Curr Osteoporos Rep       Date:  2017-08       Impact factor: 5.096

Review 9.  Plastin 3 in health and disease: a matter of balance.

Authors:  Lisa Wolff; Eike A Strathmann; Ilka Müller; Daniela Mählich; Charlotte Veltman; Anja Niehoff; Brunhilde Wirth
Journal:  Cell Mol Life Sci       Date:  2021-05-23       Impact factor: 9.261

10.  An ARHGAP25 variant links aberrant Rac1 function to early-onset skeletal fragility.

Authors:  Riikka E Mäkitie; Petra Henning; Yaming Jiu; Anders Kämpe; Konstantin Kogan; Alice Costantini; Ville-Valtteri Välimäki; Carolina Medina-Gomez; Minna Pekkinen; Isidro B Salusky; Camilla Schalin-Jäntti; Maria K Haanpää; Fernando Rivadeneira; John H Duncan Bassett; Graham R Williams; Ulf H Lerner; Renata C Pereira; Pekka Lappalainen; Outi Mäkitie
Journal:  JBMR Plus       Date:  2021-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.